ChemicalBook > Product Catalog >API >Blood System Drugs >Anticoagulant and Antiplatelet Drugs >TICAGRELOR


TICAGRELOR Suppliers list
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Products Intro: Product Name:TICAGRELOR
Purity:99% Package:1000KG;;100KG;10KG;5KG;1KG
Company Name: Shanghai Yingrui Biopharma Co., Ltd.
Tel: +86-21-33585366
Products Intro: Product Name:TICAGRELOR
Purity:99% Package:100g;500g;1kg;25kg...
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Products Intro: Product Name:Ticagrelor
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Casorganics US Corp
Tel: +17326109938
Products Intro: Product Name:Ticagrelor
Purity:99.98% Package:1KG;USD|5KG;USD|25KG;USD|50KG;USD
Company Name: BOC Sciences
Tel: 1-631-619-7922
Products Intro: Product Name:Ticagrelor
Purity:>=98% Package:1g;169USD

Lastest Price from TICAGRELOR manufacturers

  • Ticagrelor
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:274693-27-5
  • Min. Order: 1g
  • Purity: 99%+
  • Supply Ability: 50kg/month
  • Ticagrelor
  • US $169.00 / g
  • 2020-05-17
  • CAS:274693-27-5
  • Min. Order: 1g
  • Purity: ≥98%
  • Supply Ability: 10kg
  • ticagrelor
  • US $1.00 / Kg/Drum
  • 2019-07-19
  • CAS:274693-27-5
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 999tons
TICAGRELOR Basic information
Indications and Usage Mechanisms of Action Clinical Research
Synonyms:1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-;Ticagrelor, >=98%;Ticagrelo;Ticargrelor;Brilinta;Possia;Ticagrelor and intermediates;Ticagrelor Standards
Product Categories:AZD6140;Ticagrelor;Cardiovascular APIs;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
Mol File:274693-27-5.mol
TICAGRELOR Chemical Properties
Boiling point 777.6±70.0 °C(Predicted)
density 1.67
Safety Information
Safety Statements 24/25
HS Code 29335990
MSDS Information
TICAGRELOR Usage And Synthesis
Indications and UsageTicagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world’s first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.
Mechanisms of ActionReversibly acts on the 2 purine receptor (purinoceptor 2, P2,) subtype P2Y12, of vascular smooth muscle cells (VSMC,) does not require metabolic activation, and has a significant inhibitory effect on platelet aggregation induced by adenosine diphosphate (ADP.)
Clinical ResearchTicagrelor was approved by the U.S. Food and Drug Administration (FDA) on the basis of PLATO clinical studies. PLATO was a 43 country, 862 center randomized, double-blind, multi-centered study which included 18,624 patients hospitalized for ACS. Patients were randomly given either aspirin plus ticagrelor, or aspirin plus clopidogrel, two antiplatelet regimens. The study showed a 16% reduction in risk of heart attack, stroke, or death in the group taking Ticagrelor compared to those who took clopidogrel. The PLATO study demonstrated the benefits of Ticagrelor for patient survival, and is currently widely recommended as a treatment strategy for ACS. In addition, at the same time it reduces operative myocardial infarction and thrombosis after stent implantation, it also does not increase the overall risk of fatal bleeding and other serious adverse effects.
Ticagrelor however has two shortcomings. First, it must be taken twice a day, compared to once a day for clopidogrel, and secondly, it may cause adverse effects such as breathing difficulties, significantly more than with the latter. Its half-life is only 12 hours, and taken twice a day, a challenge for patients with poor compliance. In practice, it has also been found that around 20% of patients treated with clopidogrel do not follow their prescriptions, and these patients are even less likely to take the prescribed doses when using ticagrelor. Thus, as a rapidly reversible drug, direct withdrawal will likely increase the risk of acute thrombosis, causing myocardial infection or stroke.
DescriptionIn December 2010, the P2Y12 receptor antagonist ticagrelor (also known as AZD6140) was approved in Europe for the treatment of acute coronary syndrome (ACS), a condition that covers several clinical symptoms with the potential to cause acute myocardial ischemia (MI). ADP binds to two purinergic receptors, the P2Y1 and P2Y12 receptors. The action of ADP binding to the P2Y12 receptor results in activation of the GP Ⅱb/Ⅲa (integrin) receptor.GP Ⅱb/Ⅲa initiates and prolongs platelet aggregation, which in turn results in the cross-linking of platelets through fibrin and finally thrombus formation. Inhibition of ADP stimulation of the P2Y12 receptor has been found to be an effective strategy for managing the atherothrombotic events associated with ACS and potentially resulting from percutaneous coronary intervention (PCI, stent implantation) .
Chemical PropertiesWhite Solid
OriginatorAstra-Zeneca (United Kingdom)
UsesTicagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS)
UsesTicagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively
DefinitionChEBI: A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for p evention of thromboembolic events in patients with acute coronary syndrome.
Brand nameBrilique and Possia in the European Union
TICAGRELOR Preparation Products And Raw materials
Tag:TICAGRELOR(274693-27-5) Related Product Information
(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide Cyclopropanamine,2-(3,4-difluorophenyl)-(1R,2S) -(2R,3R)-2,3-dihydroxybutanedioate (1:1) 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid 4,6-dichloro-2-propylthiopyrimidine-5-amine (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine (2R)-Hydroxy(phenyl)ethanoate Ethanol, 2-[[(3aR,4S,6R,6aS)-6-[[5-aMino-6-chloro-2-(propylthio)-4-pyriMidinyl]aMino]tetrahydro-2,2-diMethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]- (1R trans)-2-(3,4-difluorophenyl)cyclopropane amine CarbaMicacid,N-[(3aS,4R,6S,6aR)-tetrahydro-6-hydroxy-2,2-diMethyl-4H-cyclopenta-1,3-dioxol-4-yl]-,phenylMethyl ester Everolimus Y27632 (hydrochloride) Selumetinib MK-2206 2HCl ABT 263 N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide Prasugrel Clopidogrel TICAGRELOR tranylcypromine